Compare Transocean Ltd (RIG) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Transocean Ltd vs ResMed Inc. — how do they compare? Transocean Ltd trades at $5.53 (market cap $6.19B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 5.2× Transocean Ltd's market cap, and ResMed Inc. pays a 1.16% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Transocean Ltd for 18 Days and ResMed Inc. for 51 Days on average.
| RIG | RMD | |
|---|---|---|
Market Cap | $6.19B | $31.89B |
Volume | 30,564,415 | 618,314 |
Sector | Energy | Health |
52-Week High | $7.58 | $277.88 |
52-Week Low | $3.08 | $182.82 |
Typical Hold Time | 18 Days | 51 Days |
Enterprise Value | $10.80B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Transocean (RIG) trades at $5.51, up 2.23% with a bullish technical signal despite mixed earnings. The company shows improving cash flow trends ($995M operating cash flow projected for 2026) and maintains a strong gross margin of 85.45%, though net income remains negative. Recent developments include DOJ approval for the $5.8 billion Valaris acquisition and new contract awards totaling $380 million, providing operational momentum in the tightening offshore drilling market.
RIG presents a speculative opportunity with significant deleveraging potential through improved cash flow generation, but carries substantial risk from high debt levels and consistent net losses. Analyst sentiment is divided with 39% buy ratings, reflecting the balance between offshore cycle strength and financial leverage concerns. The stock's upside depends on successful debt reduction and execution of the Valaris integration.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
